Get the Stockscreener App
0.0152
10.88%
-0.00185
Galera Therapeutics Inc stock is traded at $0.0152, with a volume of 4,700.
It is down -10.88% in the last 24 hours and down -10.88% over the past month.
See More
Previous Close:
$0.017
Open:
$0.01666
24h Volume:
4,700
Relative Volume:
4.23
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-69.68M
P/E Ratio:
-0.00802
EPS:
-1.89
Net Cash Flow:
$-48.93M
1W Performance:
-10.88%
1M Performance:
-10.88%
6M Performance:
-23.49%
1Y Performance:
-96.95%
1-Day Range:
$0.0167
$0.0167
1-Week Range:
$0.0167
$0.0167
52-Week Range:
$0.0167
$0.019
Galera Therapeutics Inc Stock (GRTX) Company Profile
Name
Galera Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare GRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.0167 | 0 | 0 | -69.68M | -48.93M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.37 | 106.87B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
487.38 | 63.14B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.64 | 61.27B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
850.52 | 51.94B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.66 | 35.04B | 398.11M | -1.03B | -868.57M | -5.7032 |
Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-19-21 | Downgrade | BofA Securities | Buy → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Dec-02-19 | Initiated | BTIG Research | Buy |
| Dec-02-19 | Initiated | BofA/Merrill | Buy |
| Dec-02-19 | Initiated | Citigroup | Buy |
| Dec-02-19 | Initiated | Credit Suisse | Neutral |
View All
Galera Therapeutics Inc Stock (GRTX) Latest News
Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research
Legend Biotech CorporationAmerican Depositary Shares (NQ: - FinancialContent
Radiation-Induced Oral Mucositis in Head and Neck Cancer Market is expected to reach USD 1.63 billion by 2034 - openPR.com
North American Morning Briefing : Stock Futures -2- - MarketScreener
Oral Mucositis Market Growth, Trends, Consumer Demand and Key Opportunities - openPR.com
Galera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Lelezard
Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - The Manila Times
Oral Mucositis Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com
Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Radiation-induced Esophagitis Treatment Market Size in 7MM - openPR.com
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics extends agreement deadline - Investing.com
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights
Galera Therapeutics holds annual stockholder meeting - Investing.com
Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of H - ScienceDirect.com
Oral Mucositis Treatment Market Size to Hit USD 3.72 Billion by 2034 - Precedence Research
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - VISTA.Today
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Twelve option delistings on December 23rd - TipRanks
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA Today
The 2024 Biotech Graveyard - Fierce Biotech
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart.com
Galera stockholders reject liquidation plan - Investing.com
UroGen Appoints Chris Degnan as Chief Financial Officer - Yahoo Finance
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire
Galera Therapeutics faces Nasdaq delisting - Investing.com
"Trimming the Fat or Losing the Muscle? August 2024’s Biotech Layoff Frenzy Signals Strategic 'Adjustments' in the Name of Efficiency" - BioSpectrum Asia
Galera Therapeutics Announces Plan of Liquidation and Dissolution Amid Financial Updates - MyChesCo
Galera Therapeutics set to shut down one year after devastating FDA rejection - The Business Journals
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
Biopharma layoff tracker 2023: Atreca, Galera, INOVIO and more cut staff - PharmaLive
Why Galera Therapeutics (GRTX) Stock Is Nosediving - TradingView
Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics - Hunt Scanlon Media
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Galera Therapeutics Enacts Plan to Deter Hostile Takeovers - TipRanks
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer - PR Newswire
Oral Mucositis Treatment Market Size & Share Report, 2032 - Global Market Insights
Radiotherapy Induced Oral Mucositis Treatment Market, 2032 - Global Market Insights
Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals’ Board - Dallas Innovates
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates - Yahoo Finance
Pre-market Movers: AIMD, HSDT, ETNB, AKRO, BIVI..... - RTTNews
Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - TradingView
Galera Therapeutics Inc Stock (GRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
1.95%
Cap:
|
Volume (24h):